News & Updates

Intravesical interferon instillation appears to benefit women with interstitial cystitis (IC), with a recent study showing that the approach helps improve patient-reported and objective outcomes compared with hyaluronic acid without serious adverse events.

Patients with atrial fibrillation (AF) who take oral anticoagulants (OACs) and selective serotonin reuptake inhibitors (SSRIs) at the same time appear to have a higher likelihood of major bleeding.

Clinicians may favour prescribing sodium-glucose cotransporter 2 (SGLT2) inhibitors to patients with both type 2 diabetes (T2D) and nonalcoholic fatty liver disease (NAFLD), with the drugs having potential benefits in terms of NAFLD regression and reduced incidences of adverse liver-related outcomes, according to a study.

In the treatment of individuals with depression and anxiety, therapeutic single-dose psilocybin appears to be tolerable, with acute adverse effects that are resolved within 48 hours, according to the results of a meta-analyses.

Patients with longstanding axial spondyloarthritis (axSpA) and those with nonspondyloarthritis (non-SpA) with chronic back pain show no significant difference in their response to nonsteroidal anti-inflammatory drugs (NSAIDs), according to a study.

Maintenance treatment with niraparib, a potent, highly selective PARP* inhibitor, provides a favourable overall survival (OS) trend compared with placebo in Chinese patients with platinum-sensitive recurrent ovarian cancer (PSROC), regardless of germline BRCA (gBRCA) mutation status, according to the final analysis of the NORA trial presented at SGO 2024.

Exposure to paclitaxel-coated devices (PCDs) does not appear to increase the risk of death among patients who are undergoing endovascular revascularization for lower limb peripheral artery disease, suggest the results of DETECT, a nationwide, retrospective cohort study. In contrast, exposure to PADs may even help lower the risk of mortality.